Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants

References

• Brown J, Chien C, Timmins P, et al. Compartmental absorption modeling and site of absorption studies to determine feasibility of an extended-release formulation of an HIV-1 attachment inhibitor phosphate ester prodrug. J Pharm Sci. 2013;102(6):1742–1751.
   PubMed Web of Science ®Google Scholar
• Nettles RE, Chien C, Elefant E, et al. Single and multiple dose pharmacokinetics and safety in non‐HIV‐infected healthy subjects dosed with BMS‐663068, an oral HIV attachment inhibitor. Paper presented at: 12th International Workshop on Clinical Pharmacology of HIV Therapy; April 13–15, 2011; Miami, FL. Abstract O_04.
   Google Scholar
• Langley DR, Kimura SR, Sivaprakasam P, et al. Homology models of the HIV-1 attachment inhibitor BMS-626529 bound to gp120 suggest a unique mechanism of action. Proteins. 2015;83(2):331–350.
   PubMed Web of Science ®Google Scholar
• Pancera M, Lai Y-T, Bylund T, et al. Crystal structures of trimeric HIV envelope with entry inhibitors BMS-378806 and BMS-626529. Nat Chem Biol. 2017;13(10):1115–1122.
   PubMed Web of Science ®Google Scholar
• Lataillade M, Krystal M, Ackerman P. Conceptualization and design of mechanism of action for temsavir. Paper presented at: 16th European AIDS Conference; October 25–27, 2017; Milan, Italy. Abstract.
   Google Scholar
• Nowicka‐Sans B, Gong Y-F, McAuliffe B, et al. In vitro antiviral characteristics of HIV‐1 attachment inhibitor BMS‐626529, the active component of the prodrug BMS‐663068. Antimicrob Agents Chemother. 2012;56(7):3498–3507.
   PubMed Web of Science ®Google Scholar
• Li Z, Zhou N, Sun Y, et al. Activity of the HIV-1 attachment inhibitor BMS-626529, the active component of the prodrug BMS-663068, against CD4-independent viruses and HIV-1 envelopes resistant to other entry inhibitors. Antimicrob Agents Chemother. 2013;57(9):4172–4180.
   Web of Science ®Google Scholar
• Ray N, Hwang C, Healy MD, et al. Prediction of virological response and assessment of resistance emergence to the HIV-1 attachment inhibitor BMS-626529 during 8-day monotherapy with its prodrug BMS-663068. J Acquir Immune Defic Syndr. 2013;64(1):7–15.
   Web of Science ®Google Scholar
• Zhou N, Nowicka‐Sans B, McAuliffe B, et al. Genotypic correlates of susceptibility to HIV-1 attachment inhibitor BMS-626529, the active agent of the prodrug BMS-663068. J Antimicrob Chemother. 2014;69(3):573–581.
   Web of Science ®Google Scholar
• Lalezari JP, Latiff GH, Brinson C, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug BMS-663068 in treatment-experienced individuals: 24 week results of AI438011, a phase 2b, randomised controlled trial. Lancet HIV. 2015;2(10):e427–e437.
   PubMed Web of Science ®Google Scholar
• Gorycki P, Magee M, Ackerman P, et al. Pharmacokinetics, metabolism and excretion of radiolabeled fostemsavir administered with or without ritonavir in healthy male subjects. Paper presented at: 19th International Workshop on Clinical Pharmacology of Antiviral Therapy; May 22–24, 2018; Baltimore, MD. Abstract 42.
   Google Scholar
• Landry I, Vakkalagadda B, Lubin S, et al. HIV-1 attachment inhibitor prodrug BMS-663068: PK assessment with rosuvastatin. Paper presented at: Conference on Retroviruses and Opportunistic Infections; February 22–25, 2016; Boston, MA. Abstract 460.
   Google Scholar
• Abel S, Russell D, Whitlock LA, Ridgway CE, Nedderman ANR, Walker DK. Assessment of the absorption, metabolism and absolute bioavailability of maraviroc in healthy male subjects. Br J Clin Pharmacol. 2008;65(s1):60–67.
   Google Scholar
• Hyland R, Dickins M, Collins C, Jones H, Jones B. Maraviroc: in vitro assessment of drug-drug interaction potential. Br J Clin Pharmacol. 2008;66(4):498–507.
   PubMed Web of Science ®Google Scholar
• Abel S, Russell D, Taylor-Worth RJ, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(s1):27–37.
   Google Scholar
• Abel S, Jenkins TM, Whitlock LA, Ridgway CE, Muirhead GJ. Effects of CYP3A4 inducers with and without CYP3A4 inhibitors on the pharmacokinetics of maraviroc in healthy volunteers. Br J Clin Pharmacol. 2008;65(s1):38–46.
   Google Scholar
• Kimoto E, Vourvahis M, Scialis RJ, Eng H, Rodrigues AD, Varma MVS. Mechanistic evaluation of the complex drug-drug interactions of maraviroc: contribution of cytochrome P450 3A, P-glycoprotein and organic anion transporting polypeptide 1B1. Drug Metab Dispos. 2019;47(5):493–503.
   PubMed Web of Science ®Google Scholar
• Siccardi M, D'Avolio A, Nozza S, et al. Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T > C polymorphism. Pharmacogenet Genomics. 2010;20(12):759–765.
   PubMed Web of Science ®Google Scholar
• Walker DK, Abel S, Comby P, Muirhead GJ, Nedderman ANR, Smith DA. Species differences in the disposition of the CCR5 antagonist, UK-427,857, a new potential treatment for HIV. Drug Metab Dispos. 2005;33(4):587–595.
   PubMed Web of Science ®Google Scholar
• Abel S, Back DJ, Vourvahis M. Maraviroc: pharmacokinetics and drug interactions. Antivir Ther. 2009;14(5):607–618.
   PubMed Web of Science ®Google Scholar
• SELZENTRY® (maraviroc) [package insert]. Research Triangle Park, NC: ViiV Healthcare; October, 2020.
   Google Scholar
• Sevinsky H, Magee M, Ackerman P, et al. The effect of food on the pharmacokinetics of the HIV-1 attachment inhibitor temsavir, the active moiety of the prodrug fostemsavir. Paper presented at: 18th International Workshop on Clinical Pharmacology of Antiviral Therapy; June 14–17, 2017; Chicago, IL. Poster 23.
   Google Scholar
• Kozal M, Aberg J, Pialoux G, et al. Fostemsavir in adults with multidrug-resistant HIV-1 infection. N Engl J Med. 2020;382(13):1232–1243.
   PubMed Web of Science ®Google Scholar
• Lataillade M, Lalezari JP, Kozal M, et al. Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV. 2020;7(11):e740–e751.
   PubMed Web of Science ®Google Scholar
• Ackerman P, Wilkin T, Pierce A, et al. Clinical impact of antiretroviral agents used in optimized background therapy with fostemsavir in heavily treatment-experienced adults with HIV-1: exploratory analyses of the phase 3 BRIGHTE study. Paper presented at: 11th IAS Conference on HIV Science; July 18‒21, 2021; Virtual. Poster PEB155.
   Google Scholar